RUNX1 and acute myeloid leukemia: Given the heterogeneity of CN-AML patients, the current GE-based risk score associated with EVI1 expression would be of clinical value to identify patients who may benefit from intensive therapeutic strategies and to develop new targeted treatments in high risk patients.